My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Csl Ltd Sp/Adr (OP:CSLLY)

52.19 -1.83 (-3.38%)

Streaming Delayed Price Updated: 10:29 AM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Csl Ltd Sp/Adr

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗

June 20, 2025

The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.

Via Investor's Business Daily

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗

February 07, 2025

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

Via Benzinga

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines ↗

November 02, 2022

Via Benzinga

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks ↗

August 17, 2022

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses ↗

September 30, 2024

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...

Via Benzinga

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia ↗

April 26, 2024

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.

Via Benzinga

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside ↗

December 13, 2023

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

5 Diverse Medical Stocks To Buy For 2023 And Beyond ↗

April 08, 2023

Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and...

Via Talk Markets

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗

March 20, 2023

Reuters

Via Benzinga

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗

March 20, 2023

Via Benzinga

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗

February 21, 2023

Via Benzinga

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗

November 23, 2022

Via Benzinga

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? ↗

November 02, 2022

The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.

Via InvestorPlace

Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗

August 22, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021 ↗

December 14, 2021

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.